secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-003781
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd announces PEMGARDA neutralizes dominant SARS-CoV-2 variant XEC in vitro
-------------------------------------------------------------------------------

- New data show PEMGARDA (pemivibart) maintains neutralizing activity against XEC, which with KP.3.1.1 accounts for 69% of U.S. variants per CDC.
- Data submitted to FDA; update to PEMGARDA Fact Sheet for Healthcare Providers expected.
- Pemivibart has shown consistent activity across 39 distinct SARS-CoV-2 variants over nearly three years.
- Company does not anticipate meaningful change to neutralization if epitope remains intact as since Omicron BA.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025003781/0000950170-25-003781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025003781/ivvd-20250110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer